Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
In 2019, UCB is planning to have its climate action targets approved by the @sciencetargets initiative. #UCB #ScienceBasedTargets https://t.co/EkPm4jWjIl https://t.co/9PVGKGp4Pg
— UCB News (@ucb_news) 23.05.2019 -
As 6,000 influencers and advocates arrive in Vancouver, UCB is excited to continue our conversations on how we can deliver for women https://t.co/LuCJbUlp38 https://t.co/nhrAZ2K6tm
— UCB News (@ucb_news) 23.05.2019 -
A UCB survey of over 4,000 women aged 60+ revealed more than a third said their doctor had never spoken to them about #osteoporosis and #fragilityfractures, despite affecting 1 in 3 women over 50 in their lifetime. Take action and assess your risk today.
— UCB News (@ucb_news) 23.05.2019
